Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data

by | Feb 15, 2026 | Uncategorized

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments